Table 1.

Demographics, clinical, and genotype data of the study participants

Line ID	Group	Sex	Age at biopsy	MAPT haplotype	Age at onset (years)	Disease duration (years)	aUPDRS motor decline	aMMSE score decline	iPSC lines
1	healthy	M	69	H1/H1
2	healthy	F	67	H1/H1
3	healthy	M	80	H2/H2
4	healthy	F	75	H1/H1					healthy 4
5	healthy	M	70	H1/H2					healthy 5
6	healthy	F	70	H1/H2
7	healthy	M	71	H1/H1
8	healthy	F	61	H1/H2					healthy 8
9	healthy	F	66	H2/H2
10	healthy	F	58	H1/H1
	ratio F:M/mean ± SD	6:4	68.7 ± 6.3
11	PD	M	56	H1/H1	34	23	−0.32	0
12	PD	M	60	H1/H1	48	12	−0.43	0
13	PD	F	77	H2/H2	65	12	1.48	0
14	PD	F	67	H1/H1	56	12	0.76	−0.07
15	PD	F	59	H1/H1	45	15	−1.39	0
16	PD	F	80	H1/H2	69	11	0.39	−0.07
17	PD	M	80	H2/H2	49	33	1.70	0
18	PD	F	87	H1/H1	72	15	0.25	−0.12
19	PD	F	77	H1/H1	56	24	−0.42	−0.25
20	PD	M	75	H1/H1	63	13	−1.18	0
21	PD	M	77	H1/H1	66	11	−1.68	0
22	PD	F	71	H1/H1	62	14	0	−0.47
23	PD	M	72	H1/H1	70	2	1.71	−0.44
24	PD	M	81	H1/H1	76	6	1.88	0.14
25	PD	F	44	H1/H1	40	5	−3.56	0.15
26	PD	F	79	H1/H1	NA	NA	NA	NA	PD 26
27	PD	F	68	H1/H1	55	15	1.65	0
28	PD	M	57	H1/H1	50	8	NA	NA	PD 28
	ratio F:M/mean ± SD	10:8	70.4 ± 11.2		57.4 ± 11.9	12.5 ± 7.1	0.05 ± 1.5	−0.07 ± 0.18

MMSE, Mini-Mental State Examination; NA, not available; UPDRS, Unified Parkinson’s Disease Rating Scale.

^aAverage rate of decline per year over a minimum of 2 years.